Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Stable HFrEF of Ischemic Etiology (EVO-HF Pilot)
2017-004656-30Phase 2Active
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of evolocumab in coronary arteriosclerosis, heart failure with reduced ejection fraction (HFrEF), sponsored by Germans Trias i Pujol Research Institute. Started Sep 2018; status: active.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosisheart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2017-004656-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004656-30.